"Keeping our people with mammalian meat allergy safe when having potentially life-saving treatment for colorectal cancer "

"Keeping our people with mammalian meat allergy safe when having potentially life-saving treatment for colorectal cancer "

Nicholas Della Marta, Alexander Yuile, Claire Mok, Joe Wei, Meredith Oatley, Tracey Skinner, Samuel Miller, Sheryl van Nunen, Stephen Clarke, Connie Diakos, Madhawa De Silva, David Chan, Gavin Marx, Nick Pavlakis.. A Protocol for pre-treatment testing or antibodies to alpha-galactose-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions. Australasian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane, Australia. 18-21 November, 2024.

Cetuximab has been shown to improve survival in patients with KRAS wildtype metastatic colorectal cancer. However, high rates of hypersensitivity reactions (HSRs) limit its use, with HSR rates up to 10-20%. A major driver of cetuximab HSR is from pre-formed antibody response to galactose-1,3-alpha-galactose (alpha-gal). Evidence from retrospective studies supports alpha-gal pre-screening in this setting. We are the first to report on the impact of prospective alpha-gal antibody screening on cetuximab HSR

To read the full poster please click here

Melanie Burk